Rising Genetic Disorders Drive Hereditary Breast and Ovarian Cancer Market to $8.57 Billion by 2028

The new report published by The Business Research Company, titled "Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.28 billion in 2023 to $6.72 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $8.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13209&type=smp

Genetic Disorders Driving Growth In Hereditary Breast And Ovarian Cancer Syndrome Treatment Market
The rise in genetic disorders is expected to propel the growth of the hereditary breast and ovarian cancer syndrome treatment market going forward. Newborn screening is a physical examination that screens all babies shortly after birth for specific health conditions, which health professionals use to identify and treat specific requirements before they make a baby sick. Newborn screening could identify babies at high risk of developing breast cancer and ovarian cancer, allowing them to start preventive measures early. For instance, in 2022, according to the Texas Department of State Health Services, a US-based state health agency, the total specimens received for newborn screening increased by 4.3% from 729,347 in 2021 to 761,000 in 2022. Further, around 394,000 babies were screened, and 1,130 babies were affected by one of the NBS disorders in 2022. Therefore, the rise in genetic disorders is driving the growth of the hereditary breast and ovarian cancer syndrome treatment market.

Innovative Treatment Approaches In The Hereditary Breast And Ovarian Cancer Syndrome Market
Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market are adopting new treatment options, such as comprehensive risk tests, to provide reliable services to the customers. A complete risk assessment test is a tool that helps to identify an individual's risk of developing a disorder or experiencing a symptom of a disease. For instance, in February 2023, Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a ground-breaking comprehensive risk assessment test, a type of treatment for breast and ovarian cancer. It combines gene mutation testing for breast and ovarian cancers, hereditary and non-hereditary risk factors, and the GeneType risk score for both cancers. It has a unique approach that combines the detection of the 13 primary actionable breast and ovarian cancer susceptibility genes with the GeneType test platform. The new test platform addresses women over 30 who, outside of unusual genetic alterations, are at higher risk of developing breast and ovarian cancer in the general population.

The hereditary breast and ovarian cancer syndrome treatment market covered in this report is segmented -
1) By Treatment: Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments
2) By Diagnosis: Genetic Testing, Magnetic Resonance Imaging (MRI), Mammography, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13209&type=discount

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC , AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited , Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care

Contents of the report:
1. Executive Summary
2. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report Structure
3. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Trends And Strategies
4. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market - Macro Economic Scenario
5. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Size And Growth
…..
27. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/hereditary-breast-and-ovarian-cancer-syndrome-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.